Skip to content
  • Home
  • Book Bag: 0 items (Full)
    • English
    • 日本語
    • 中文(简体)
    • 中文(繁體)
    • اللغة العربية
  • About
Advanced
  • 364 KRAS mutations in patients...
  • Cite this
  • Text this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Add to Book Bag Remove from Book Bag
  • Permanent link

364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status

Bibliographic Details
Published in:Journal for ImmunoTherapy of Cancer
Main Authors: Enriqueta Felip, Marina Chiara Garassino, Edward B Garon, Roy S Herbst, Razvan Cristescu, Martin Reck, Yi-Long Wu, Byoung Chul Cho, Michael Boyer, Delvys Rodriguez-Abreu, Hidehito Horinouchi, Rina Hui, Gilberto de Castro, Gilberto Lopes, Dariusz M Kowalski, Hande Z Turna, Tony SK Mok, Shirish M Gadgeel, Kazuo Kasahara, Julie Kobie, Yongjin Li, Mark A Ayers, M Catherine Pietanza
Format: Article
Language:English
Published: BMJ Publishing Group 2021-11-01
  • Holdings
  • Description
  • Similar Items
  • Staff View

Similar Items

  • Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
    by: Marina C. Garassino, MD, et al.
    Published: (2023-01-01)
  • Corrigendum to “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]
    by: Marina C. Garassino, MD, et al.
    Published: (2025-10-01)
  • Pemetrexed and Platinum Plus Pembrolizumab in Patients With Metastatic Nonsquamous NSCLC by Tumor Burden at Baseline: A Post Hoc Efficacy Analysis of KEYNOTE-189
    by: Shirish Gadgeel, MD, et al.
    Published: (2022-11-01)
  • Real-World Treatment Patterns and Outcomes of First-Line Immunotherapy Among Patients With Advanced Nonsquamous NSCLC Harboring BRAF, MET, or HER2 Alterations
    by: Marina C. Garassino, MD, et al.
    Published: (2023-10-01)
  • Prevalence of EGFR Mutations in Patients With Resected Stage I to III Nonsquamous Non–Small Cell Lung Cancer: Results of India Cohort
    by: Ullas Batra, et al.
    Published: (2025-04-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs